Scribe Therapeutics Inc.

SCTX

NASDAQHealthcareBiotechnology

公司概况

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Benjamin L. Oakes
上市以来: 2026年7月24日
雇员: 89